Free Trial
→ China’s message to Trump (From Porter & Company) (Ad)tc pixel

Michele Holcomb Acquires 29,239 Shares of PureTech Health (LON:PRTC) Stock

Written by MarketBeat
September 24, 2025
PureTech Health logo with Medical background

Key Points

  • Michele Holcomb purchased 29,239 shares of PureTech Health stock at an average price of GBX 125, totaling approximately £36,548.75.
  • As of the latest trading, PureTech Health shares opened at GBX 128 and have fluctuated between a 1-year low of GBX 100.40 and a 1-year high of GBX 178.
  • PureTech Health is focused on developing treatments for diseases related to the nervous, gastrointestinal, and immune systems, featuring a microbiome immune system drug-discovery platform.
  • Five stocks to consider instead of PureTech Health.

PureTech Health plc (LON:PRTC - Get Free Report) insider Michele Holcomb acquired 29,239 shares of the business's stock in a transaction that occurred on Tuesday, September 23rd. The shares were acquired at an average cost of GBX 125 per share, for a total transaction of £36,548.75.

PureTech Health Price Performance

Shares of LON:PRTC opened at GBX 128 on Wednesday. PureTech Health plc has a 1-year low of GBX 100.40 and a 1-year high of GBX 178. The business's 50 day moving average is GBX 129.15 and its 200-day moving average is GBX 129.62. The company has a current ratio of 3.68, a quick ratio of 2.51 and a debt-to-equity ratio of 45.82. The firm has a market capitalization of £309.36 million, a PE ratio of 752.94 and a beta of 1.02.

About PureTech Health

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.